Dec 07, 2020 7:00 am EST Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting
Dec 06, 2020 11:00 pm EST Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
Nov 15, 2020 10:00 am EST Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting
Nov 12, 2020 8:30 am EST Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
Nov 09, 2020 4:01 pm EST Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress
Nov 02, 2020 4:01 pm EST Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020
Sep 14, 2020 8:30 am EDT Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress
Sep 11, 2020 8:00 am EDT Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188